State of the Art - SGLT2 inhibitors in cardiovascular disease

31 August 2019 (11:00 - 11:18)

Organised by:

Video

Slides

Sign in for access options

About the speaker

Professor Marc Sabatine

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

4 More presentations in this session

Presentation thumbnail

Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58

Doctor T. Zelniker (Vienna, AT)

Abstract Slides Video

Presentation thumbnail

Qualifying event proximity, cardiovascular risk, and benefit of empagliflozin in patients with type 2 diabetes and stable atherosclerosis in the EMPA-REG OUTCOME trial

Doctor J. Udell (Toronto, CA)

Abstract Slides Video

Presentation thumbnail

SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes

Doctor C. Noergaard (Aalborg, DK)

Abstract Slides Video

Presentation thumbnail

Integrating SGLT2 inhibitors in diabetes treatment: a guide for cardiologists

Professor N. Sattar (Glasgow, GB)

Access the full session

Session thumbnail

New frontiers: SGLT2 inhibitors in cardiorenal disease

The Event

ESC Congress 2019

31 August 2019 11:00 CET

You may be interested in

Congress Presentation

Coronary risk reduction intervention for siblings and offspring of patients with premature coronary heart disease: the criso project.

ESC TV Today

Episode 26: Lp(a): the future starts now - Myocardial infarction in older age and frailty

Webinar

Risk assessment and lipid management in primary prevention

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources